نتائج البحث - David C. Dalgarno

  • يعرض 1 - 12 نتائج من 12
تنقيح النتائج
  1. 1
    High-throughput prediction of protein conformational distributions with subsampled AlphaFold2

    High-throughput prediction of protein conformational distributions with subsampled AlphaFold2 حسب Gabriel Monteiro da Silva, Jennifer Y. Cui, David C. Dalgarno, George P. Lisi, Brenda M. Rubenstein

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    <sup>1</sup>H NMR studies of calmodulin

    <sup>1</sup>H NMR studies of calmodulin حسب David C. Dalgarno, Rachel E. Klevit, Barry A. Levine, Robert J. P. Williams, Z Dobrowolski, W. Drabikowski

    منشور في 1984
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Proton Nuclear‐Magnetic‐Resonance Spectroscopy of Myosin Subfragment 1 Isoenzymes

    Proton Nuclear‐Magnetic‐Resonance Spectroscopy of Myosin Subfragment 1 Isoenzymes حسب H. Paul PRINCE, Hylary R. Trayer, Gillian D. Henry, Ian P. Trayer, David C. Dalgarno, Barry A. Levine, Peter D. Cary, Christopher H. Turner

    منشور في 1981
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

    Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance حسب Mohammad Azam, Valentina Nardi, William C. Shakespeare, Chester A. Metcalf, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, Piotr Sliz, Darren R. Veach, William G. Bornmann, Bayard Clarkson, David C. Dalgarno, Tomi K. Sawyer, George Q. Daley

    منشور في 2006
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen

    Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen حسب Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David C. Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

    Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML حسب Thomas O’Hare, Roy M. Pollock, Eric P. Stoffregen, Jeffrey Keats, Omar Mohammed Abdullah, Erika M. Mosesón, Victor M. Rivera, Hao Tang, Chester A. Metcalf, Regine S. Bohacek, Yihan Wang, Raji Sundaramoorthi, William C. Shakespeare, David C. Dalgarno, Tim Clackson, Tomi K. Sawyer, Michael W. Deininger, Brian J. Druker

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds

    Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds حسب David C. Dalgarno, Thilo Stehle, Surinder S. Narula, P. Schelling, Marie Rose van Schravendijk, Susan Adams, Lawrence Andrade, Jeff Keats, Mary K. Ram, Lei Jin, Trudy H. Grossman, Ian A. MacNeil, Chester A. Metcalf, William C. Shakespeare, Yihan Wang, Terry Keenan, Raji Sundaramoorthi, Regine S. Bohacek, Manfred Weigele, Tomi K. Sawyer

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

    Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma حسب Liz Y. Han, Charles N. Landen, José G. Treviño, Jyotsnabaran Halder, Yvonne G. Lin, Aparna A. Kamat, Tae‐Jin Kim, William M. Merritt, Robert L. Coleman, David M. Gershenson, William C. Shakespeare, Yihan Wang, Raji Sundaramoorth, Chester A. Metcalf, David C. Dalgarno, Tomi K. Sawyer, Gary E. Gallick, Anil K. Sood

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Mobocertinib (TAK-788): A Targeted Inhibitor of<i>EGFR</i>Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

    Mobocertinib (TAK-788): A Targeted Inhibitor of<i>EGFR</i>Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer حسب Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker, Alexandra E. Gould, Shuai Li, Scott Wardwell, Sara Nadworny, Yaoyu Ning, Sen Zhang, Wei‐Sheng Huang, Yongbo Hu, Feng Li, Matthew T. Greenfield, Stephan G. Zech, Biplab Das, Narayana I. Narasimhan, Tim Clackson, David C. Dalgarno, William C. Shakespeare, Michael Fitzgerald, Johara Chouitar, Robert Griffin, Shengwu Liu, Kwok‐Kin Wong, Xiaotian Zhu, Victor M. Rivera

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance حسب Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu, Christopher A. Eide, Victor M. Rivera, Frank Wang, Lauren T. Adrian, Tianjun Zhou, Wei-Sheng Huang, Qihong Xu, Chester A. Metcalf, Jeffrey W. Tyner, Marc Loriaux, Amie S. Corbin, Scott Wardwell, Yaoyu Ning, Jeffrey Keats, Yihan Wang, Raji Sundaramoorthi, Mathew Thomas, Dong Zhou, J. T. Snodgrass, Lois Commodore, Tomi K. Sawyer, David C. Dalgarno, Michael W. Deininger, Brian J. Druker, Tim Clackson

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with <i>in vivo</i> antiresorptive activity

    Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with <i>in vivo</i> antiresorptive activity حسب William C. Shakespeare, Michael G. Yang, Regine S. Bohacek, Franklin Cerasoli, Karin J. Stebbins, Raji Sundaramoorthi, Mihai Azimioara, Chi B. Vu, Selvi Pradeepan, Chester A. Metcalf, Chad A. Haraldson, Taylor Merry, David C. Dalgarno, Surinder S. Narula, Marcos Hatada, Xiaode Lu, Marie Rose van Schravendijk, Susan Adams, Shelia M. Violette, Jeremy A. Smith, Wei Guan, Catherine Bartlett, Jay Herson, John D. Iuliucci, Manfred Weigele, Tomi K. Sawyer

    منشور في 2000
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

    The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models حسب Sen Zhang, Rana Anjum, Rachel M. Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott Wardwell, David F. Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei‐Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish K. Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana I. Narasimhan, Frank Wang, Juan J. Miret, Xiaotian Zhu, Tim Clackson, David C. Dalgarno, William C. Shakespeare, Victor M. Rivera

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: